Thousands of sickle cell disease patients will get access to a new “life-changing” treatment on the NHS on May 3 after the approval and introduction of a novel medication that has the potential to greatly enhance their quality of life. The National Institute for Health and Care Excellence (Nice) in England has approved the medication Voxelotor for use in patients with the condition who are 12 years or older. The drug, taken as a daily tablet, is said to considerably enhance the quality of life for sickle cell patients by lowering their need for blood transfusions, which results in fewer hospit…